Quantcast

Latest Rufinamide Stories

2014-06-30 12:26:21

LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Seizures - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/seizures_pipeline_review_h1_2013.html Seizures - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Seizures - Pipeline Review, H1 2014', provides an overview of the Seizures's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Seizures,...

2011-12-15 00:20:01

Tokyo, Dec 15, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited (Eisai Canada) has received approval from Health Canada for Halaven (eribulin mesylate), a novel anticancer agent discovered and developed by Eisai, for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an...

2011-01-25 01:22:00

HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial seizures in patients with...

2011-01-13 07:21:00

HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide). Commenting...

2010-10-01 14:25:38

More than 50 percent reduction in partial seizure frequency; safety, efficacy confirmed Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS). Details of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy. Epilepsy affects up to 2% of the...

2009-04-28 00:00:00

S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ -- - New Option for Treatment of Epilepsy Patients With Partial Onset Seizures Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis Portela), and Eisai Europe Limited (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), today announced that the novel once daily anti-epileptic Zebinix(R)*...

2009-02-19 09:02:00

LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and...

2008-11-20 19:35:58

The U.S. Food and Drug Administration has approved a new drug, rufinamide -- marketed as Banzel -- to treat severe epilepsy. The drug is to be used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome. This approval offers another treatment option for patients who suffer from these debilitating, severe seizures, Dr. Russell Katz of the FDA's Center for Drug Evaluation and Research said Thursday in a statement. Lennox-Gastaut syndrome is a severe form of epilepsy...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.